Advertisement

Current Advances in the Psychopharmacology of Psychosomatic Medicine

  • Amarendra N. SinghEmail author
Chapter

Abstract

Psychosomatic medicine is a way of approaching health problems, and psychosomatic disorders in general are pathological expression of biological, psychological, and socioecological parameters of human health.

Keywords

Anxiety Disorder Anorexia Nervosa Selective Serotonin Reuptake Inhibitor Bulimia Nervosa Binge Eating Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Singh, A. N. (2006). Psychosomatic medicine and psychopharmacology, symbiosis of present future. International Congress Series, 1287, 12–16. Elsevier BV, Amsterdam.CrossRefGoogle Scholar
  2. 2.
    Singh, A. N. (2006). Recent advances in the psychopharmacology of psychosomatic medicine. International Congress Series, 1287, 206–212. Elsevier BV, Amsterdam.CrossRefGoogle Scholar
  3. 3.
    Singh, A. N., & Nagata, K. (2003). Recent advances in the psychopharmacology of psychosomatic medicine. Pyschiatria et Neurologia Japonica, 105, 441–447.Google Scholar
  4. 4.
    Singh, A. N. (1992). Pharmacological therapy in psychosomatic medicine. Japanese Journal of Psychosomatic Medicine, 32, 589–598.Google Scholar
  5. 5.
    Singh, A. N. (2010, September 10–12). Recent advances in the psychopharmacology of psychosomatic medicine. Paper presented at the 14th Congress of the Asian College of Psychosomatic Medicine, Beijing, China.Google Scholar
  6. 6.
    Boyer, W. (1995). Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: A meta-analysis. International Clinical Psychopharmacology, 10, 45–49.PubMedCrossRefGoogle Scholar
  7. 7.
    Bradwejn, J., Ahokas, A., Stein, D. J., et al. (2005). Venlafaxine extended release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. The British Journal of Psychiatry, 187, 352–359.PubMedCrossRefGoogle Scholar
  8. 8.
    Sheehan, D. V., Raj, A. B., Sheehan, K. H., et al. (1990). Is buspirone effective for panic disorder? Journal of Clinical Psychopharmacology, 10, 3–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Simin, N. M., Hoge, E. A., Fischman, D., et al. (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. The Journal of Clinical Psychiatry, 67, 381–385.CrossRefGoogle Scholar
  10. 10.
    Sepede, G., de Berardis, D., Gambi, F., et al. (2006). Olanzapine augmentation in treatment-resistant panic disorder: A 12-week, fixed-dose, open-label trial. Journal of Clinical Psychopharmacology, 26, 45–49.PubMedCrossRefGoogle Scholar
  11. 11.
    Keck, P. E., Jr., McElroy, S. L., Tugrul, K. C., et al. (1993). Anti-epileptic drugs for the treatment of panic disorder. Neuropsychobiology, 27, 150–153.PubMedCrossRefGoogle Scholar
  12. 12.
    Sarchiapone, M., Amore, M., De Risio, S., et al. (2003). Mirtazapine in the treatment of panic disorder: An open-label trial. International Clinical Psychopharmacology, 18, 35–38.PubMedCrossRefGoogle Scholar
  13. 13.
    Bertani, A., Perna, G., Migliarese, G., et al. (2004). Comparison of the treatment with paroxetine and reboxetine in panic disorder: A randomized, single-blind study. Pharmacopsychiatry, 37, 206–210.PubMedCrossRefGoogle Scholar
  14. 14.
    Singh, A. N. (1983). A clinical picture of benzodiazepine dependence and guidelines for reducing dependence (pp. 14–18). Princeton, NJ: Excerpta Medica Office.Google Scholar
  15. 15.
    Matthew, S. J., Amiel, J. M., Coplan, J. D., et al. (2005). Open-label trial of riluzole in generalized anxiety disorder. The American Journal of Psychiatry, 162, 2379–2381.CrossRefGoogle Scholar
  16. 16.
    Jefferson, J. W., & Greist, J. H. (1996). The pharmacotherapy of obsessive-compulsive disorder. Psychiatric Annals, 26, 202–209.Google Scholar
  17. 17.
    Silver, J. M., Sandberg, D. P., & Hales, R. E. (1990). New approaches in the pharmacotherapy of post-traumatic stress disorder. The Journal of Clinical Psychiatry, 51(Supp. 10), 33–38.Google Scholar
  18. 18.
    Lipper, S., Davidson, J. R., Grady, T. A., et al. (1986). Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics, 27, 849–854.PubMedCrossRefGoogle Scholar
  19. 19.
    Fesler, F. A. (1991). Valproate in combat-related post-traumatic stress disorder. The Journal of Clinical Psychiatry, 52, 361–364.PubMedGoogle Scholar
  20. 20.
    Baldwin, D., Bobes, J., Stein, D. J., et al. (1999). Paroxetine in social phobia/social anxiety disorder: Randomised, double-blind, placebo-controlled study. The British Journal of Psychiatry, 175, 120–126.PubMedCrossRefGoogle Scholar
  21. 21.
    Baldwin, D., DeMartinis, N., Mallick, R. (2004, February 9–13). Patient-reported functioning in SAD and improvement with treatment: A comparison of venlafaxine XR, paroxetine and placebo. Program and abstracts of the International Congress of Biological Psychiatry, Sydney, Australia.Google Scholar
  22. 22.
    Stein, M. B., Fyer, A. J., Davidson, J. R., et al. (1999). Fluvoxamine treatment of social phobia: A double-blind, placebo-controlled study of fluvoxamine. 115, 128–134.Google Scholar
  23. 23.
    Van Ameringan, M. A., Lane, R. M., Walker, J. R., et al. (2001). Sertraline treatment of generalized social phobia: A 20 week, double-blind, placebo-controlled study. The American Journal of Psychiatry, 158, 275–281.CrossRefGoogle Scholar
  24. 24.
    Singh, A. N. (2006). Therapeutic uses of oriental approaches in psychosomatic medicine. International Congress Series, 1287, 91–96. Elsevier BV, Amsterdam.CrossRefGoogle Scholar
  25. 25.
    Singh, A. N. (1992). Non-pharmacological approaches of Hindu Buddhist medicine in psychosomatic disorders. Japanese Journal of Psychosomatic Medicine, 32, 417–425.Google Scholar
  26. 26.
    Singh, A. N., & Janier, A. K. (1999). Recent advances in the treatment of depression. Journal of the Indian Medical Association, 1, 19–24.Google Scholar
  27. 27.
    Perlis, R. H. (2007). Pharmacogenetic studies of antidepressant response: How far from the clinic? The Psychiatric Clinics of North America, 30, 125–138.PubMedCrossRefGoogle Scholar
  28. 28.
    Smits, K. M., Smits, L. J., Schouten, J. S., et al. (2007). Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clinical Therapeutics, 29, 691–702.PubMedCrossRefGoogle Scholar
  29. 29.
    Liu, Z., Zhu, F., Wang, G., et al. (2007). Association study of corticotrophin-releasing hormone receptor 1 gene polymorphisms and antidepressant response in major depressive disorder. Neuroscience Letters, 414(2), 155–158. Elsevier, Ireland.PubMedCrossRefGoogle Scholar
  30. 30.
    Smits, K., Smits, L., Peeters, F., et al. (2007). Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. International Clinical Psychopharmacology, 22, 137–143.PubMedCrossRefGoogle Scholar
  31. 31.
    Hu, X. Z., Rush, A. J., Charney, D., et al. (2007). Association between a functional serotonin transporter polymorphism and citalopram treatment in adult outpatients with major depression. Archives of General Psychiatry, 64, 783–792.PubMedCrossRefGoogle Scholar
  32. 32.
    Singh, A. N. (2004). Recent advances in the pharmacotherapy of insomnia. WHO Lecture Series, 6(1), 46–55.Google Scholar
  33. 33.
    Ikemi, Y. (1966). Integration of occidental and oriental psychosomatic treatment in integration of Eastern and Western psychosomatic medicine (pp. 37–46). Kyushu: Kyushu University Press.Google Scholar
  34. 34.
    Lieb, R., Meinschmidt, G., & Aryaya, R. (2007). Epidemiology of the association between somatoform disorders and anxiety and depressive disorders: An update. Psychosomatic Medicine, 69, 860–863.PubMedCrossRefGoogle Scholar
  35. 35.
    Phillips, K. A., Albertini, R. S., & Rasmussen, S. A. (2002). A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Archives of General Psychiatry, 59, 381–388.PubMedCrossRefGoogle Scholar
  36. 36.
    Fallon, B. A. (2004). Pharmacotherapy of somatoform disorders. Journal of Psychosomatic Research, 56, 455–460.PubMedCrossRefGoogle Scholar
  37. 37.
    Mitchell, J. E., de Zwaan, M., & Roerig, J. L. (2003). Drug therapy for patients with eating disorders. Current Drug Targets. CNS and Neurological Disorders, 2(1), 17–29. Bentham Science Publishers, Oak Park, IL.PubMedCrossRefGoogle Scholar
  38. 38.
    Yager, J. (2008). Binge eating disorder: The search for better treatments. The American Journal of Psychiatry, 165, 4–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Advokat, C., & Kutlesic, V. (1995). Pharmacotherapy of the eating disorders: A commentary. Neuroscience and Biobehavioural Reviews, 19(1), 59–66. Elsevier, USA.CrossRefGoogle Scholar
  40. 40.
    Nickel, C., Tritt, K., Muehlbacher, M., et al. (2005). Topiramate treatment in bulimia nervosa patients: A randomized, double-blind, placebo-controlled trial. International Journal of Eating Disorders, 38, 295–300.PubMedCrossRefGoogle Scholar
  41. 41.
    Appolinario, J. C., Bacaltchuk, J., Sicheri, R., et al. (2003). A randomized double-blind placebo-controlled study of sibutramine in the treatment of binge eating disorder. Archives of General Psychiatry, 60, 1109–1116.PubMedCrossRefGoogle Scholar
  42. 42.
    Silviera, R. O., Zanatto, V., Appolinario, J. C., et al. (2005). An open trial of reboxetine in obese patients with binge eating disorder. Eating and Weight Disorders, 10, e93–e96.Google Scholar
  43. 43.
    Snoeck, E., Peer, A., Mannens, G., et al. (1995). Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Journal of Biomedical Life Science - Psychopharmacology, 122, 223–229.Google Scholar
  44. 44.
    Percudani, M., Barbui, C., Fortino, I., et al. (2005). Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly. Journal of Clinical Psychopharmacology, 25, 468–470.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Psychopharmacology, Department of Psychiatry, Pharmacology and NeurosciencesQueen’s UniversityKingstonCanada

Personalised recommendations